GWPharma - Preliminary Results for the Year Ended 30 September 2009Relevance: 
...9: GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its preliminary results for the year ended 30 September 2009.
OPERATIONAL HIGHLIGHTS
Positive results in Sativex Phase III MS spasticity trial and long term r...
GWPharma - Preliminary Results for the Year Ended 30 September 2003Relevance: 
Regulatory dossier for Sativex® submitted to the UK authorities in March 2003
Sativex regulatory assessment process well advanced. Completion expected during the second quarter of 2004.
Production, supply chain and marketing teams prepared for launch of Sativex
Marketing arrangements signed with...
GWPharma - SativexRelevance: 
Sativex R
Mechanism of Action
Home
Sativex
Sativex
Sativex® is a cannabinoid medicine for the treatment of spasticity due to multiple sclerosis which is also in development in cancer pain and neuropathic pain of various origins...
Now approved in the UK, Spain, Germany, Denmark, the Czech Rep...
GWPharma - Information on Obtaining SativexRelevance:
Prescriber Information Information on Obtaining Sativex
Summary of Product Characteristics
MS Trials Review
Patient Organisations
Publications
Sativex R
Mechanism of Action
Home
Sativex
Prescriber Information
Information on Obtaining Sativex
Information on Obtaining Sativex
The position...
GWPharma - Sativex in CanadaRelevance:
Prescriber Information Information on Obtaining Sativex
Summary of Product Characteristics
MS Trials Review
Patient Organisations
Publications
Sativex R
Mechanism of Action
Home
Sativex
Prescriber Information
Sativex in Canada
Sativex in Canada
In Canada, as well as being approved for t...
GWPharma - Sativex in New ZealandRelevance:
Prescriber Information Information on Obtaining Sativex
Summary of Product Characteristics
MS Trials Review
Patient Organisations
Publications
Sativex R
Mechanism of Action
Home
Sativex
Prescriber Information
Sativex in New Zealand
Sativex in New Zealand
Sativex® can currently be prescr...
GWPharma - Sativex in IsraelRelevance:
Prescriber Information Information on Obtaining Sativex
Summary of Product Characteristics
MS Trials Review
Patient Organisations
Publications
Sativex R
Mechanism of Action
Home
Sativex
Prescriber Information
Sativex in Israel
Sativex in Israel
Sativex has also now achieved approval in ...
GWPharma - UK InformationRelevance:
Sativex R
Mechanism of Action
Home
Sativex
UK Information
UK Information
Sativex® is approved in the UK as a prescription medicine for the treatment of spasticity due to multiple sclerosis
There is now a dedicated site for UK residents. Please visit:
www.sativex.co.uk
Alternatively please ...
GWPharma - Sativex in SpainRelevance:
Prescriber Information Information on Obtaining Sativex
Summary of Product Characteristics
MS Trials Review
Patient Organisations
Publications
Sativex R
Mechanism of Action
Home
Sativex
Prescriber Information
Sativex in Spain
Sativex in Spain
Almirall S.A. is GW’s partner in Europe and ...
